Previous close | 53.99 |
Open | 53.92 |
Bid | 53.91 x 1800 |
Ask | 53.92 x 4000 |
Day's range | 53.51 - 54.40 |
52-week range | 38.48 - 61.71 |
Volume | |
Avg. volume | 27,492,225 |
Market cap | 302.484B |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | 12.36 |
EPS (TTM) | 4.36 |
Earnings date | 26 July 2022 - 01 Aug 2022 |
Forward dividend & yield | 1.60 (2.96%) |
Ex-dividend date | 12 May 2022 |
1y target est | 59.15 |
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
NEW YORK, May 26, 2022--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). Fast Track is a process designed to facilitate the development and ex